Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study
Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless...
Gespeichert in:
| Veröffentlicht in: | BMJ open 2020-09, Vol.10 (9), p.e038194-e038194, Article 038194 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e038194 |
|---|---|
| container_issue | 9 |
| container_start_page | e038194 |
| container_title | BMJ open |
| container_volume | 10 |
| creator | Zhou, Mi Chan, Esther W. Hai, Jo Jo Wong, Chun Ka Lau, Yuk Ming Huang, Duo Lam, Cheung Chi Tam, Chor Cheung Frankie Wong, Yiu Tung Anthony Yung, See Yue Arthur Chan, Ki Wan Kelvin Feng, Yingqing Tan, Ning Chen, Ji-yan Yung, Chi Yui Lee, Kwok Lun Choi, Chun Wai Lam, Ho Ng, Andrew Fan, Katherine Jim, Man Hong Yiu, Kai Hang Yan, Bryan P. Siu, Chung Wah |
| description | Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety and effectiveness of NOACs have not been evaluated in patients with AF with underlying moderate or severe mitral stenosis (MS), hence the recommended stroke prevention strategy remains warfarin therapy.
Method and analysis MS remains disproportionately prevalent in Asian countries compared with the developed countries. This prospective, randomised, open-label trial with blinded endpoint adjudication aims to evaluate the safety and efficacy of dabigatran for stroke prevention in AF patients with moderate or severe MS. Patients with AF aged >= 18 years with moderate or severe MS not planned for valvular intervention in the coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg or 150 mg two times per day or warfarin with international normalised ratio 2-3 in an open-label design. Patients with estimated creatinine clearance |
| doi_str_mv | 10.1136/bmjopen-2020-038194 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2446672426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7a029335b61f4ef28dd44439b479ad63</doaj_id><sourcerecordid>2446672426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-46cfaa8fa3e6b4c2c4cd270d83a12a62f7aabde63165d198a67bbe54f307146b3</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYlPZL0BClrgZYgF_xUl2gVS1DCptYtJgt5Y_TopLahc7Hdpf4lfiflBtXJGbWM5zHp1z8hbFS4LfEcLEe71chBX4kmKKS8wa0vInxTHFnJcCV9XTB-ej4iSlBc4Pr9qqos-LI0bbuqEYHxe_r2MYggn9GYpqcMGrHpDyFllIbu5R6NB0rN1cDVF51IWIboYYfgC6jnALflOBZh6Nh-hUjy6cjq7vtyLkPLoKU8haQJs6uIMI6MplU58t4ENyCZ1Ox7ezaXl18-YcqdyDt2HpEtgztJ2vVxp6lIa1vX9RPOtUn-Bk_x4V3y4-fp18Li-_fJpNxpel4W07lFyYTqmmUwyE5oYabiytsW2YIlQJ2tVKaQuCEVFZ0jZK1FpDxTuGa8KFZqNitvPaoBZyFd1SxXsZlJPbixDnUsXBmR5krTBtGau0IB2HjjbWcs5Zq3ndKitYdn3YuVZrvQRr8sby9I-kj794913Ow52sK4qb7B4Vp3tBDD_XkAaZt2Mg79hDWCdJOReippyKjL7-B12Edcw_NFNCcEpom6MzKtiOMjGkFKE7NEOw3ERL7qMlN9GSu2jlqlcP5zjU_A1SBt7ugF-gQ5eMA2_ggOXsVXXuATf5RKpMN_9PT9ywDdQkrP3A_gCVee2T</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2664212911</pqid></control><display><type>article</type><title>Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study</title><source>BMJ Open Access Journals</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Zhou, Mi ; Chan, Esther W. ; Hai, Jo Jo ; Wong, Chun Ka ; Lau, Yuk Ming ; Huang, Duo ; Lam, Cheung Chi ; Tam, Chor Cheung Frankie ; Wong, Yiu Tung Anthony ; Yung, See Yue Arthur ; Chan, Ki Wan Kelvin ; Feng, Yingqing ; Tan, Ning ; Chen, Ji-yan ; Yung, Chi Yui ; Lee, Kwok Lun ; Choi, Chun Wai ; Lam, Ho ; Ng, Andrew ; Fan, Katherine ; Jim, Man Hong ; Yiu, Kai Hang ; Yan, Bryan P. ; Siu, Chung Wah</creator><creatorcontrib>Zhou, Mi ; Chan, Esther W. ; Hai, Jo Jo ; Wong, Chun Ka ; Lau, Yuk Ming ; Huang, Duo ; Lam, Cheung Chi ; Tam, Chor Cheung Frankie ; Wong, Yiu Tung Anthony ; Yung, See Yue Arthur ; Chan, Ki Wan Kelvin ; Feng, Yingqing ; Tan, Ning ; Chen, Ji-yan ; Yung, Chi Yui ; Lee, Kwok Lun ; Choi, Chun Wai ; Lam, Ho ; Ng, Andrew ; Fan, Katherine ; Jim, Man Hong ; Yiu, Kai Hang ; Yan, Bryan P. ; Siu, Chung Wah</creatorcontrib><description>Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety and effectiveness of NOACs have not been evaluated in patients with AF with underlying moderate or severe mitral stenosis (MS), hence the recommended stroke prevention strategy remains warfarin therapy.
Method and analysis MS remains disproportionately prevalent in Asian countries compared with the developed countries. This prospective, randomised, open-label trial with blinded endpoint adjudication aims to evaluate the safety and efficacy of dabigatran for stroke prevention in AF patients with moderate or severe MS. Patients with AF aged >= 18 years with moderate or severe MS not planned for valvular intervention in the coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg or 150 mg two times per day or warfarin with international normalised ratio 2-3 in an open-label design. Patients with estimated creatinine clearance <30 mL/min, or with a concomitant indication for antiplatelet therapy will be excluded. The primary outcome is a composite of stroke and systemic embolism. Secondary outcomes are ischaemic stroke, systemic embolism, haemorrhagic stroke, intracranial haemorrhage, major bleeding and death. The estimated required sample size is approximately 686 participants.
Ethics and dissemination The study protocol has been approved by the Institutional Review Board of the University of Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong for Fung Yiu King Hospital, Grantham Hospital, Queen Mary Hospital and Tung Wah Hospital in Hong Kong. Results will be published in peer-reviewed journals.</description><identifier>ISSN: 2044-6055</identifier><identifier>EISSN: 2044-6055</identifier><identifier>DOI: 10.1136/bmjopen-2020-038194</identifier><identifier>PMID: 32978200</identifier><language>eng</language><publisher>LONDON: Bmj Publishing Group</publisher><subject>Ablation ; Administration, Oral ; Adolescent ; Adult ; Anemia ; Anticoagulants ; Anticoagulants - adverse effects ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Blood pressure ; Brain Ischemia - drug therapy ; Cardiac arrhythmia ; Cardiovascular disease ; Cardiovascular Medicine ; Clinical medicine ; Clinical trials ; Creatinine ; Dabigatran - adverse effects ; Disease prevention ; Drug dosages ; Embolisms ; Endocarditis ; General & Internal Medicine ; Glycoproteins ; Hemoglobin ; Hong Kong ; Humans ; Hypertension ; Informed consent ; Ischemia ; Life expectancy ; Life Sciences & Biomedicine ; Medicine, General & Internal ; Mitral Valve Stenosis - complications ; Prospective Studies ; Prostheses ; Randomized Controlled Trials as Topic ; Science & Technology ; Stroke ; Stroke - drug therapy ; Stroke - etiology ; Stroke - prevention & control ; Thrombocytopenia ; Treatment Outcome</subject><ispartof>BMJ open, 2020-09, Vol.10 (9), p.e038194-e038194, Article 038194</ispartof><rights>Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>9</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000576640800015</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c499t-46cfaa8fa3e6b4c2c4cd270d83a12a62f7aabde63165d198a67bbe54f307146b3</citedby><cites>FETCH-LOGICAL-c499t-46cfaa8fa3e6b4c2c4cd270d83a12a62f7aabde63165d198a67bbe54f307146b3</cites><orcidid>0000-0002-0864-9512 ; 0000-0002-7602-9470 ; 0000-0001-5205-9440</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520829/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520829/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2104,2116,27931,27932,28255,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32978200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Mi</creatorcontrib><creatorcontrib>Chan, Esther W.</creatorcontrib><creatorcontrib>Hai, Jo Jo</creatorcontrib><creatorcontrib>Wong, Chun Ka</creatorcontrib><creatorcontrib>Lau, Yuk Ming</creatorcontrib><creatorcontrib>Huang, Duo</creatorcontrib><creatorcontrib>Lam, Cheung Chi</creatorcontrib><creatorcontrib>Tam, Chor Cheung Frankie</creatorcontrib><creatorcontrib>Wong, Yiu Tung Anthony</creatorcontrib><creatorcontrib>Yung, See Yue Arthur</creatorcontrib><creatorcontrib>Chan, Ki Wan Kelvin</creatorcontrib><creatorcontrib>Feng, Yingqing</creatorcontrib><creatorcontrib>Tan, Ning</creatorcontrib><creatorcontrib>Chen, Ji-yan</creatorcontrib><creatorcontrib>Yung, Chi Yui</creatorcontrib><creatorcontrib>Lee, Kwok Lun</creatorcontrib><creatorcontrib>Choi, Chun Wai</creatorcontrib><creatorcontrib>Lam, Ho</creatorcontrib><creatorcontrib>Ng, Andrew</creatorcontrib><creatorcontrib>Fan, Katherine</creatorcontrib><creatorcontrib>Jim, Man Hong</creatorcontrib><creatorcontrib>Yiu, Kai Hang</creatorcontrib><creatorcontrib>Yan, Bryan P.</creatorcontrib><creatorcontrib>Siu, Chung Wah</creatorcontrib><title>Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study</title><title>BMJ open</title><addtitle>BMJ OPEN</addtitle><addtitle>BMJ Open</addtitle><description>Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety and effectiveness of NOACs have not been evaluated in patients with AF with underlying moderate or severe mitral stenosis (MS), hence the recommended stroke prevention strategy remains warfarin therapy.
Method and analysis MS remains disproportionately prevalent in Asian countries compared with the developed countries. This prospective, randomised, open-label trial with blinded endpoint adjudication aims to evaluate the safety and efficacy of dabigatran for stroke prevention in AF patients with moderate or severe MS. Patients with AF aged >= 18 years with moderate or severe MS not planned for valvular intervention in the coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg or 150 mg two times per day or warfarin with international normalised ratio 2-3 in an open-label design. Patients with estimated creatinine clearance <30 mL/min, or with a concomitant indication for antiplatelet therapy will be excluded. The primary outcome is a composite of stroke and systemic embolism. Secondary outcomes are ischaemic stroke, systemic embolism, haemorrhagic stroke, intracranial haemorrhage, major bleeding and death. The estimated required sample size is approximately 686 participants.
Ethics and dissemination The study protocol has been approved by the Institutional Review Board of the University of Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong for Fung Yiu King Hospital, Grantham Hospital, Queen Mary Hospital and Tung Wah Hospital in Hong Kong. Results will be published in peer-reviewed journals.</description><subject>Ablation</subject><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anemia</subject><subject>Anticoagulants</subject><subject>Anticoagulants - adverse effects</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Blood pressure</subject><subject>Brain Ischemia - drug therapy</subject><subject>Cardiac arrhythmia</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Medicine</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Dabigatran - adverse effects</subject><subject>Disease prevention</subject><subject>Drug dosages</subject><subject>Embolisms</subject><subject>Endocarditis</subject><subject>General & Internal Medicine</subject><subject>Glycoproteins</subject><subject>Hemoglobin</subject><subject>Hong Kong</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Informed consent</subject><subject>Ischemia</subject><subject>Life expectancy</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, General & Internal</subject><subject>Mitral Valve Stenosis - complications</subject><subject>Prospective Studies</subject><subject>Prostheses</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Science & Technology</subject><subject>Stroke</subject><subject>Stroke - drug therapy</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Thrombocytopenia</subject><subject>Treatment Outcome</subject><issn>2044-6055</issn><issn>2044-6055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYlPZL0BClrgZYgF_xUl2gVS1DCptYtJgt5Y_TopLahc7Hdpf4lfiflBtXJGbWM5zHp1z8hbFS4LfEcLEe71chBX4kmKKS8wa0vInxTHFnJcCV9XTB-ej4iSlBc4Pr9qqos-LI0bbuqEYHxe_r2MYggn9GYpqcMGrHpDyFllIbu5R6NB0rN1cDVF51IWIboYYfgC6jnALflOBZh6Nh-hUjy6cjq7vtyLkPLoKU8haQJs6uIMI6MplU58t4ENyCZ1Ox7ezaXl18-YcqdyDt2HpEtgztJ2vVxp6lIa1vX9RPOtUn-Bk_x4V3y4-fp18Li-_fJpNxpel4W07lFyYTqmmUwyE5oYabiytsW2YIlQJ2tVKaQuCEVFZ0jZK1FpDxTuGa8KFZqNitvPaoBZyFd1SxXsZlJPbixDnUsXBmR5krTBtGau0IB2HjjbWcs5Zq3ndKitYdn3YuVZrvQRr8sby9I-kj794913Ow52sK4qb7B4Vp3tBDD_XkAaZt2Mg79hDWCdJOReippyKjL7-B12Edcw_NFNCcEpom6MzKtiOMjGkFKE7NEOw3ERL7qMlN9GSu2jlqlcP5zjU_A1SBt7ugF-gQ5eMA2_ggOXsVXXuATf5RKpMN_9PT9ywDdQkrP3A_gCVee2T</recordid><startdate>20200925</startdate><enddate>20200925</enddate><creator>Zhou, Mi</creator><creator>Chan, Esther W.</creator><creator>Hai, Jo Jo</creator><creator>Wong, Chun Ka</creator><creator>Lau, Yuk Ming</creator><creator>Huang, Duo</creator><creator>Lam, Cheung Chi</creator><creator>Tam, Chor Cheung Frankie</creator><creator>Wong, Yiu Tung Anthony</creator><creator>Yung, See Yue Arthur</creator><creator>Chan, Ki Wan Kelvin</creator><creator>Feng, Yingqing</creator><creator>Tan, Ning</creator><creator>Chen, Ji-yan</creator><creator>Yung, Chi Yui</creator><creator>Lee, Kwok Lun</creator><creator>Choi, Chun Wai</creator><creator>Lam, Ho</creator><creator>Ng, Andrew</creator><creator>Fan, Katherine</creator><creator>Jim, Man Hong</creator><creator>Yiu, Kai Hang</creator><creator>Yan, Bryan P.</creator><creator>Siu, Chung Wah</creator><general>Bmj Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0864-9512</orcidid><orcidid>https://orcid.org/0000-0002-7602-9470</orcidid><orcidid>https://orcid.org/0000-0001-5205-9440</orcidid></search><sort><creationdate>20200925</creationdate><title>Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study</title><author>Zhou, Mi ; Chan, Esther W. ; Hai, Jo Jo ; Wong, Chun Ka ; Lau, Yuk Ming ; Huang, Duo ; Lam, Cheung Chi ; Tam, Chor Cheung Frankie ; Wong, Yiu Tung Anthony ; Yung, See Yue Arthur ; Chan, Ki Wan Kelvin ; Feng, Yingqing ; Tan, Ning ; Chen, Ji-yan ; Yung, Chi Yui ; Lee, Kwok Lun ; Choi, Chun Wai ; Lam, Ho ; Ng, Andrew ; Fan, Katherine ; Jim, Man Hong ; Yiu, Kai Hang ; Yan, Bryan P. ; Siu, Chung Wah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-46cfaa8fa3e6b4c2c4cd270d83a12a62f7aabde63165d198a67bbe54f307146b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ablation</topic><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anemia</topic><topic>Anticoagulants</topic><topic>Anticoagulants - adverse effects</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Blood pressure</topic><topic>Brain Ischemia - drug therapy</topic><topic>Cardiac arrhythmia</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Medicine</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Dabigatran - adverse effects</topic><topic>Disease prevention</topic><topic>Drug dosages</topic><topic>Embolisms</topic><topic>Endocarditis</topic><topic>General & Internal Medicine</topic><topic>Glycoproteins</topic><topic>Hemoglobin</topic><topic>Hong Kong</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Informed consent</topic><topic>Ischemia</topic><topic>Life expectancy</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, General & Internal</topic><topic>Mitral Valve Stenosis - complications</topic><topic>Prospective Studies</topic><topic>Prostheses</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Science & Technology</topic><topic>Stroke</topic><topic>Stroke - drug therapy</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Thrombocytopenia</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Mi</creatorcontrib><creatorcontrib>Chan, Esther W.</creatorcontrib><creatorcontrib>Hai, Jo Jo</creatorcontrib><creatorcontrib>Wong, Chun Ka</creatorcontrib><creatorcontrib>Lau, Yuk Ming</creatorcontrib><creatorcontrib>Huang, Duo</creatorcontrib><creatorcontrib>Lam, Cheung Chi</creatorcontrib><creatorcontrib>Tam, Chor Cheung Frankie</creatorcontrib><creatorcontrib>Wong, Yiu Tung Anthony</creatorcontrib><creatorcontrib>Yung, See Yue Arthur</creatorcontrib><creatorcontrib>Chan, Ki Wan Kelvin</creatorcontrib><creatorcontrib>Feng, Yingqing</creatorcontrib><creatorcontrib>Tan, Ning</creatorcontrib><creatorcontrib>Chen, Ji-yan</creatorcontrib><creatorcontrib>Yung, Chi Yui</creatorcontrib><creatorcontrib>Lee, Kwok Lun</creatorcontrib><creatorcontrib>Choi, Chun Wai</creatorcontrib><creatorcontrib>Lam, Ho</creatorcontrib><creatorcontrib>Ng, Andrew</creatorcontrib><creatorcontrib>Fan, Katherine</creatorcontrib><creatorcontrib>Jim, Man Hong</creatorcontrib><creatorcontrib>Yiu, Kai Hang</creatorcontrib><creatorcontrib>Yan, Bryan P.</creatorcontrib><creatorcontrib>Siu, Chung Wah</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMJ open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Mi</au><au>Chan, Esther W.</au><au>Hai, Jo Jo</au><au>Wong, Chun Ka</au><au>Lau, Yuk Ming</au><au>Huang, Duo</au><au>Lam, Cheung Chi</au><au>Tam, Chor Cheung Frankie</au><au>Wong, Yiu Tung Anthony</au><au>Yung, See Yue Arthur</au><au>Chan, Ki Wan Kelvin</au><au>Feng, Yingqing</au><au>Tan, Ning</au><au>Chen, Ji-yan</au><au>Yung, Chi Yui</au><au>Lee, Kwok Lun</au><au>Choi, Chun Wai</au><au>Lam, Ho</au><au>Ng, Andrew</au><au>Fan, Katherine</au><au>Jim, Man Hong</au><au>Yiu, Kai Hang</au><au>Yan, Bryan P.</au><au>Siu, Chung Wah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study</atitle><jtitle>BMJ open</jtitle><stitle>BMJ OPEN</stitle><addtitle>BMJ Open</addtitle><date>2020-09-25</date><risdate>2020</risdate><volume>10</volume><issue>9</issue><spage>e038194</spage><epage>e038194</epage><pages>e038194-e038194</pages><artnum>038194</artnum><issn>2044-6055</issn><eissn>2044-6055</eissn><abstract>Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety and effectiveness of NOACs have not been evaluated in patients with AF with underlying moderate or severe mitral stenosis (MS), hence the recommended stroke prevention strategy remains warfarin therapy.
Method and analysis MS remains disproportionately prevalent in Asian countries compared with the developed countries. This prospective, randomised, open-label trial with blinded endpoint adjudication aims to evaluate the safety and efficacy of dabigatran for stroke prevention in AF patients with moderate or severe MS. Patients with AF aged >= 18 years with moderate or severe MS not planned for valvular intervention in the coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg or 150 mg two times per day or warfarin with international normalised ratio 2-3 in an open-label design. Patients with estimated creatinine clearance <30 mL/min, or with a concomitant indication for antiplatelet therapy will be excluded. The primary outcome is a composite of stroke and systemic embolism. Secondary outcomes are ischaemic stroke, systemic embolism, haemorrhagic stroke, intracranial haemorrhage, major bleeding and death. The estimated required sample size is approximately 686 participants.
Ethics and dissemination The study protocol has been approved by the Institutional Review Board of the University of Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong for Fung Yiu King Hospital, Grantham Hospital, Queen Mary Hospital and Tung Wah Hospital in Hong Kong. Results will be published in peer-reviewed journals.</abstract><cop>LONDON</cop><pub>Bmj Publishing Group</pub><pmid>32978200</pmid><doi>10.1136/bmjopen-2020-038194</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0864-9512</orcidid><orcidid>https://orcid.org/0000-0002-7602-9470</orcidid><orcidid>https://orcid.org/0000-0001-5205-9440</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2044-6055 |
| ispartof | BMJ open, 2020-09, Vol.10 (9), p.e038194-e038194, Article 038194 |
| issn | 2044-6055 2044-6055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2446672426 |
| source | BMJ Open Access Journals; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Ablation Administration, Oral Adolescent Adult Anemia Anticoagulants Anticoagulants - adverse effects Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Blood pressure Brain Ischemia - drug therapy Cardiac arrhythmia Cardiovascular disease Cardiovascular Medicine Clinical medicine Clinical trials Creatinine Dabigatran - adverse effects Disease prevention Drug dosages Embolisms Endocarditis General & Internal Medicine Glycoproteins Hemoglobin Hong Kong Humans Hypertension Informed consent Ischemia Life expectancy Life Sciences & Biomedicine Medicine, General & Internal Mitral Valve Stenosis - complications Prospective Studies Prostheses Randomized Controlled Trials as Topic Science & Technology Stroke Stroke - drug therapy Stroke - etiology Stroke - prevention & control Thrombocytopenia Treatment Outcome |
| title | Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-08T00%3A09%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protocol,%20rationale%20and%20design%20of%20DAbigatran%20for%20Stroke%20PreVention%20In%20Atrial%20Fibrillation%20in%20MoDerate%20or%20Severe%20Mitral%20Stenosis%20(DAVID-MS):%20a%20randomised,%20open-label%20study&rft.jtitle=BMJ%20open&rft.au=Zhou,%20Mi&rft.date=2020-09-25&rft.volume=10&rft.issue=9&rft.spage=e038194&rft.epage=e038194&rft.pages=e038194-e038194&rft.artnum=038194&rft.issn=2044-6055&rft.eissn=2044-6055&rft_id=info:doi/10.1136/bmjopen-2020-038194&rft_dat=%3Cproquest_webof%3E2446672426%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2664212911&rft_id=info:pmid/32978200&rft_doaj_id=oai_doaj_org_article_7a029335b61f4ef28dd44439b479ad63&rfr_iscdi=true |